China Resources Boya Bio-pharmaceutical GroupLtd Balance Sheet Health
Financial Health criteria checks 6/6
China Resources Boya Bio-pharmaceutical GroupLtd has a total shareholder equity of CN¥7.5B and total debt of CN¥23.0M, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are CN¥8.0B and CN¥520.3M respectively. China Resources Boya Bio-pharmaceutical GroupLtd's EBIT is CN¥510.5M making its interest coverage ratio -11.4. It has cash and short-term investments of CN¥5.6B.
Key information
0.3%
Debt to equity ratio
CN¥23.02m
Debt
Interest coverage ratio | -11.4x |
Cash | CN¥5.57b |
Equity | CN¥7.47b |
Total liabilities | CN¥520.26m |
Total assets | CN¥7.99b |
Recent financial health updates
Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22Recent updates
Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?
Jul 25China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark
Jun 12China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30
Apr 26Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?
Apr 22China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings
Apr 01What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates
Mar 31Financial Position Analysis
Short Term Liabilities: 300294's short term assets (CN¥6.6B) exceed its short term liabilities (CN¥469.7M).
Long Term Liabilities: 300294's short term assets (CN¥6.6B) exceed its long term liabilities (CN¥50.6M).
Debt to Equity History and Analysis
Debt Level: 300294 has more cash than its total debt.
Reducing Debt: 300294's debt to equity ratio has reduced from 16.6% to 0.3% over the past 5 years.
Debt Coverage: 300294's debt is well covered by operating cash flow (2358.9%).
Interest Coverage: 300294 earns more interest than it pays, so coverage of interest payments is not a concern.